Dublin, April 14, 2026 (GLOBE NEWSWIRE) — The “Induced Pluripotent Stem Cell (iPSC) Market Report 2026” has been added to ResearchAndMarkets.com’s offering. The report delivers essential statistics, including size, regional shares, and detailed segments, offering a comprehensive understanding of the global market landscape.
The induced pluripotent stem cell (iPSC) market is experiencing robust growth, with a projected increase from $3.67 billion in 2025 to $5.75 billion by 2030, achieving a compound annual growth rate (CAGR) of over 9%. This expansion is driven by advancements in cellular reprogramming, rising ethical considerations, heightened investment in stem cell research, and increased prevalence of chronic diseases.
Significant growth is expected due to developments in regenerative medicine, a surge in personalized therapies, and rising investment in cell and gene therapies. iPSCs are gaining traction in neurological and cardiac research, with regulatory bodies supporting advanced therapeutic applications. Core market trends include the proliferation of iPSCs in disease modeling, drug discovery, toxicity testing, and the advancement of ethical alternatives to embryonic stem cells.
The prevalence of neurological disorders is a key growth driver for the iPSC market. Conditions such as Alzheimer’s disease and ALS are facilitating research into disease mechanisms and regenerative therapies. The World Federation of Neurology reported that over 40% of the global population lived with a neurological condition, underscoring the need for continued research and development in this field.
Collaborations are advancing iPSC technology, with companies focusing on regenerative medicine, improving disease models, and developing personalized treatments. Notable partnerships include SCG Cell Therapy’s collaboration with Singapore’s Agency for Science, Technology and Research, aiming to enhance cellular immunotherapies. Similarly, Theragent Inc. and Pluristyx Inc. are expanding their iPSC offerings in regenerative medicine.
Major players in the iPSC market, such as FUJIFILM Holdings, Thermo Fisher Scientific, and Lonza Group AG, are enhancing their footprints through strategic initiatives. These organizations are navigating tariff impacts by elevating local production of essential reagents, fostering regional supplier networks, and driving domestic research investments.
North America dominates the iPSC market, followed by Western Europe. The report covers regions including Asia-Pacific, North America, Europe, and more, with country-specific insights into market dynamics. As the iPSC market evolves, stakeholders are equipped with comprehensive insights into market trends and future opportunities, ensuring informed decision-making and strategic growth.
Report Scope:
- Markets Covered: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Cell Types.
- Applications: Academic Research, Drug Discovery, Regenerative Medicine, Gene Therapy.
- End-Users: Hospitals, Research Laboratories.
Key Companies: FUJIFILM Holdings, Thermo Fisher Scientific, Takara Bio, Lonza Group, Astellas Pharma, and others.
Geographies: Covering territories such as Australia, Brazil, China, France, Germany, India, Indonesia, and more.
Regions: Asia-Pacific, Southeast Asia, Western and Eastern Europe, North America, South America, Middle East, and Africa.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $4.02 Billion |
| Forecasted Market Value (USD) by 2030 | $5.75 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
The companies featured in this Induced Pluripotent Stem Cell (iPSC) market report include:
- FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc.)
- Thermo Fisher Scientific, Inc.
- Takara Bio Inc
- Lonza Group AG
- Astellas Pharma Inc.
- ViaCyte, Inc.
- Ncardia
- REPROCELL USA, Inc
- Japan Tissue Engineering Co. Ltd.
- Merck KGaA
- Cynata Therapeutics Limited
- Dainippon Sumitomo Pharma
- Shenzhen Bioscience
- Shanghai Cell Therapy Group
- Car-T Bio
- JW therapeutics
- Fosun Kite Biotechnology
- Shanghai UniCar Therapy
- SEED Biosciences SA
- Cellerix
- CellGenix
- NsGene
- TiGenix
- Renuron Group
- Smart Cells
- Genenta Science
- Biocad Rf
- Selvita
- Mabion
- Pure Biologics
- OncoArendi Therapeutics
- Proteon Pharmaceuticals
- Parexel
- BrainStorm Cell Therapeutics
- Cellular Biomedicine Group
- Pluristem Therapeutics
- Gamida Cell
- Caladrius Biosciences
- BioCanRx
- CellCAN
- CCRM
- C3i
- BioCells Argentina
- Stem Cells
- Royan Stem Cell Technology Co.
- Next BioSciences
- CryoSave
- BioHeart
For more information about this report visit https://www.researchandmarkets.com/r/g7sqr1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Induced Pluripotent Stem Cell (iPSC) Market
